Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2021 Jan 27:2021.01.27.427998.
doi: 10.1101/2021.01.27.427998.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera

Xuping Xie  1 , Yang Liu  1 , Jianying Liu  2   3 , Xianwen Zhang  1 , Jing Zou  1 , Camila R Fontes-Garfias  1 , Hongjie Xia  1 , Kena A Swanson  4 , Mark Cutler  4 , David Cooper  4 , Vineet D Menachery  2   3 , Scott Weaver  2   3 , Philip R Dormitzer  4 , Pei-Yong Shi  1   3   5   6   7
Affiliations

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera

Xuping Xie et al. bioRxiv. .

Update in

Abstract

We engineered three SARS-CoV-2 viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion+N501Y+D614G from UK; and E484K+N501Y+D614G from SA. Neutralization geometric mean titers (GMTs) of twenty BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses.

PubMed Disclaimer

Conflict of interest statement

Competing interests

X.X., V.D.M., and P.-Y.S. have filed a patent on the reverse genetic system. K.A.S., M.C., D.C., and P.R.D. are employees of Pfizer and may hold stock options. X.X., J.Z., C.R.F.G., H.X., and P.-Y.S. received compensation from Pfizer to perform the neutralization assay. Other authors declare no competing interests.

Figures

Figure 1.
Figure 1.. PRNT50s of twenty BNT162b2-vaccinated human sera against wild-type (WT) and mutant SARS-CoV-2.
(a) WT (USA-WA1/2020) and mutant N501Y. (b) WT and Δ69/70+N501Y+D614G. (c) WT and E484K+N501Y+D614G. Seven (triangles) and thirteen (circles) sera were drawn 2 and 4 weeks after the second dose of vaccination, respectively. Sera with different PRNT50s against WT and mutant viruses are connected by lines. Results in (a) were from one experiment; results in (b) and (c) were from another set of experiments. Each data point is the average of duplicate assay results.
See this image and copyright information in PMC

References

    1. Walsh EE, Frenck RW Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020. - PMC - PubMed
    1. E. V, S. M, al. CMe. Report 42 - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. https://wwwimperialacuk/mrc-global-infectious-disease-analysis/covid-19/....
    1. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Afric. medRxiv 2020. : 10.1101/2020.12.21.20248640 - DOI
    1. Xie X, Muruato A, Lokugamage KG, et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 2020;27:841–8 e3. - PMC - PubMed

Publication types